Phases of clinical research
(Redirected from Phase 2 clinical trial)
Clinical research for development of new drugs and other therapies, tests, etc. goes through a process called phases.
Preclinical research[edit | edit source]
Before going to the stage of clinical trials, researchers do what are called preclinical trials, which may include animal studies, in vitro and in vivo studies but no human subjects. The purpose of this phase is to understand about the preliminary safety of the drug or device. Preclinical research deals with the basic questions about a drug’s safety. However, it is not a substitute for studies of ways the drug will interact with the human body.
Clinical research[edit | edit source]
“Clinical research” refers to studies, or trials, that are done in people.
Drug development[edit | edit source]
As the developers design the clinical study, they will consider what they want to accomplish for each of the different Clinical Research Phases and begin the Investigational New Drug Process (IND), a process they must go through before clinical research begins.
The Investigational New Drug Process[edit | edit source]
Drug developers, or sponsors, must submit an Investigational New Drug (IND) application to FDA before beginning clinical research.
In the IND application, developers must include:
- Animal study data and toxicity (side effects that cause great harm) data
- Manufacturing information
- Clinical protocols (study plans) for studies to be conducted
- Data from any prior human research
- Information about the investigator
Phases[edit | edit source]
All new drugs and therapies go through the following 4 - 5 phases(including phase 0).
Although most drugs go through phases 1-4 after preclinical trials, there is another less often used phase called phase 0 which is designed to help understand the drugs Pharmacokinetics; particularly oral bioavailability and half-life of the drug, which is usually done at mall, subtherapeutic doses with about 10 people. However, this phase 0 is often skipped for Phase I.
Phase 1[edit | edit source]
- Study Participants: 20 to 100 healthy volunteers or people with the disease/condition.
- Length of Study: Several months
- Purpose: Safety and dosage
Approximately 70% of drugs move to the next phase
Phase 2[edit | edit source]
- Study Participants: Up to several hundred people with the disease/condition.
- Length of Study: Several months to 2 years
- Purpose: Efficacy and side effects
Approximately 33% of drugs move to the next phase
Phase 3[edit | edit source]
- Study Participants: 300 to 3,000 volunteers who have the disease or condition
- Length of Study: 1 to 4 years
- Purpose: Efficacy and monitoring of adverse reactions
Approximately 25-30% of drugs move to the next phase
Phase 4[edit | edit source]
Study Participants: Several thousand volunteers who have the disease/condition Purpose: Safety and efficacy
Cost[edit | edit source]
The overall cost of bring a new drug to the market in the West can be over a billion dollars.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD